Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.44 |
| ▸ | RORC | P51449 | 6/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7918466 | 0.86 | ALOX15 (0.49) | TRPV1RORCSCN5ASCN9ATRPM8 | |
| SCHEMBL16509478 | 0.84 | HTR5A (0.46) | TRPV1CYP2C9 | |
| SCHEMBL16502630 | 0.84 | PLA2G2D (0.46) | PLA2G2DRORCMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16502693 | 0.81 | CSNK2A2 (0.45) | PLA2G2DTRPV1RORCMEN1KMT2A | |
| SCHEMBL16502616 | 0.81 | DOT1L (0.45) | PLA2G2DTRPV1RORCMEN1KMT2A | |
| SCHEMBL4808010 | 0.80 | RORC (0.59) | TRPV1RORCPPARG | |
| SCHEMBL4952297 | 0.79 | TRPV1 (0.67) | TRPV1RORCPPARGSCN5ASCN9A | |
| SCHEMBL4182281 | 0.79 | RORC (0.53) | TRPV1RORCPPARGSCN5ASCN9A | |
| SCHEMBL16502684 | 0.78 | PLAU (0.50) | PLA2G2DRORCMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7916765 | 0.78 | PLA2G2D (0.48) | PLA2G2DRORCMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| WO-2010090304-A1 | ACYLGUANIDINE DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | HTR5A, HTR2A, HTR1A | PLA2G2D 841/4885TRPV1 899/4885RORC 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.